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Abstract
Macrophage migration inhibitory factor (MIF) plays an important role in supporting the proliferation and/or survival
of murine neural stem/progenitor cells (NSPCs); however, the downstream effectors of this factor remain unknown.
Here, we show that MIF increases the expression of Pax6 and Chd7 in NSPCs in vitro. During neural development,
the chromatin remodeling factor Chd7 (chromatin helicase-DNA-binding protein 7) is expressed in the ventricular zone
of the telencephalon of mouse brain at embryonic day 14.5, as well as in cultured NSPCs. Retroviral overexpression of
Pax6 in NSPCs increased Chd7 gene expression. Lentivirally-expressed Chd7 shRNA suppressed cell proliferation and
neurosphere formation, and inhibited neurogenesis in vitro, while decreasing gene expression of Hes5 and N-myc. In
addition, CHD7 overexpression increased cell proliferation in human embryonic stem cell-derived NSPCs (ES-NSPCs). In
Chd7 mutant fetal mouse brains, there were fewer intermediate progenitor cells (IPCs) compared to wildtype
littermates, indicating that Chd7 contributes to neurogenesis in the early developmental mouse brain. Furthermore, in
silico database analysis showed that, among members of the CHD family, CHD7 is highly expressed in human gliomas.
Interestingly, high levels of CHD7 gene expression in human glioma initiating cells (GICs) compared to normal
astrocytes were revealed and gene silencing of CHD7 decreased GIC proliferation. Collectively, our data demonstrate
that CHD7 is an important factor in the proliferation and stemness maintenance of NSPCs, and CHD7 is a promising
therapeutic target for the treatment of gliomas.
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Introduction
Macrophage migration inhibitory factor (MIF) is known
to be a proinflammatory factor in many diseases, including
atherosclerosis and rheumatoid arthritis [1]. Additionally,
MIF has been shown to induce cell proliferation in
immune cells and prostate cancer cells [2–4]. Studies of
MIF function in animals suggest that this factor may play
additional unknown roles in other diseases. In the central
nervous system (CNS), MIF expression has been reported
in the rat forebrain ventricular zone [5], yet the function of
MIF in the CNS and in NSPCs had not yet been clarified
[6]. We previously reported that MIF supports the pro-
liferation and/or survival of murine NSPCs in vitro [7].
We have also identified Sox6 as a MIF downstream sig-
naling molecule in mouse NSPCs [8]. We also recently
reported that MIF supports the proliferation of GICs
through TP53 regulation [9].
In the present study, we sought to clarify the function
of CHD7 (chromatin helicase-DNA-binding protein
seven), which has a chromodomain, a helicase domain, a
SANT-like (switching-defective protein three (Swi3),
adaptor 2 (Ada2), nuclear receptor co-repressor (N-CoR),
transcription factor (TF) IIIB-like) domain, and a BRK
(Brahma and Kismet) domain [10] in mouse NSPCs and
human ES-NSPCs. CHD7 is a member of the CHD family,
which regulates chromatin remodeling and gene regula-
tion through direct DNA-binding in a manner dependent
on the biological context, although the detailed mecha-
nisms underlying this activity remain unknown [11, 12].
In human neural crest cells and mouse ES cells, CHD7
targets active gene enhancers regulating cell-specific gene
expression [13, 14]. Mutations in CHD7 are known to be
closely linked to CHARGE syndrome (Coloboma, Heart
defects, Atresia of the choanae, Retardation of growth and
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development, Genital hypoplasia, and Ear abnormalities,
including deafness and vestibular disorders), also known
as multiple congenital abnormality [10]. In human, the
mutation of CHD7 was also identified in an autism
spectrum disorder proband [15]. In mouse, it has been
reported that Chd7 regulates the neural differentiation of
hippocampal NSPCs through SoxC or Hes5 [16, 17]. It
has also been reported that Chd7, in cooperation with
Sox10, regulates the onset of oligodendrocyte differenti-
ation and myelination, as well as remyelination after
demyelinating injury [18]. Physiological interaction
between CHD7 and SOX2 has also been reported in
human NSPCs [19]. CHD7 may thus play multiple
biological roles in concert with specific co-activators
depending on spatial and developmental status [20].
However, it remains unclear how CHD7 is regulated by
upstream regulators, especially in NSPCs.
In the present study, we show that Chd7 is expressed
in the ventricular zone and subventricular zone (SVZ) of
the ganglionic eminence (GE) and cortex in the mouse
developmental brain, in which NSPCs are located. We
further show that Chd7 expression is increased by MIF
in NSPCs in vitro, and that this effect is mediated by the
transcription factor Pax6. In addition, based on the same
mechanism, we find that CHD7 supports the proliferation
of human ES- NSPCs, as well as the cell proliferation of
GICs, suggesting that this molecule may represent a new
therapeutic target in glioma.
Methods
Animals
All interventions and animal care procedures were per-
formed in accordance with the Laboratory Animal Welfare
Act, the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health, USA), and the
Guidelines and Policies for Animal Surgery provided by
the Animal Study Committee of the Keio University and
were approved by the Animal Study Committee of Keio
University (IRB approval number 12017-0). Pregnant
C57BL/6 J mice were purchased from Sankyo Labo Service
(Tokyo, Japan). Chd7 mutant mice (Chd7Whi, EM;04923)
were purchased from the European mouse mutant archive
(www.infrafrontier.eu) and maintained on a C3HeB/FeJ
background. Genotyping was performed following to the
previous report [21].
Cell culture
NSPCs were isolated from mouse E14.5 GEs, and the
cells were cultured as neurospheres [22] at a cell density
of 50 cells/μl in neurosphere culture medium (NSP
medium) consisting of neurobasal medium (Thermo
Fisher Scientific, Carlsbad, CA, www.thermofisher.com)
supplemented with B27 (Thermo Fisher Scientific), human
recombinant (hr) EGF (20 ng/ml; Peprotech, Rocky
Hill, NJ, www.peprotech.com), and hrFGF2 (10 ng/ml;
Peprotech). Neurosphere formation assays were per-
formed at low density (20 cell/μl) in a 96-well plate. In
the experiments using NSPCs, recombinant mouse MIF
(R&D systems, Minneapolis, MN, www.rndsystems.com)
and MIF inhibitor ISO-1 (Calbiochem, La Jolla, CA,
www.merckmillipore.com) were used. NSPCs derived
from human ESCs (Human ES Cells H9-Derived) were
purchased from Thermo Fisher Scientific, and then cul-
tured and differentiated according to the product manual.
Human GICs were obtained as described previously [23].
Human astrocytes, U87MG, U251 and NSPCs were cul-
tured as reported by Fukaya et al., [9]. The study using
human NSPCs was carried out in accordance with the
principles of the Helsinki Declaration, and the Japan
Society of Obstetrics and Gynecology. Approval to use
human fetal neural tissues was obtained from the ethical
committees of both Osaka National Hospital and Keio
University. Written informed consent was obtained from
all parents through routine legal terminations performed
at Osaka National Hospital.
RNA extraction and quantitative (q) RT-PCR
Total RNA was isolated from tissues or cultured cells
using TRIZOL (Thermo Fisher Scientific). Total RNA
(0.5 μg) was subjected to the cDNA Synthesis using
ReverTra Ace® qPCR RT Master Mix with gDNA Remover
(Toyobo, Osaka, Japan, http://lifescience.toyobo.co.jp).
Quantitative RT-PCR analysis was performed with a
FastStart Universal SYBR Green Master (Roche, Tokyo,
https://roche-biochem.jp) or THUNDERBIRD Probe
qPCR Mix (Toyobo), using the ABI prism 7900 HT
Sequence Detection System (Applied Biosystems, Life
Technologies, Carlsbad, www.appliedbiosystems.com).
The PCR conditions were as follows: one cycle of 5 min
at 95 °C, followed by 40 cycles of 95 °C for 30 s, 60 °C
for 60 s, and 72 °C for 30 s (SYBR), one cycle of 1 min
at 95 °C, followed by 40 cycles of 95 °C for 30 s, 60 °C
for 60 s (Taqmanprobe). PCR reactions were performed
in triplicate. Relative gene expression levels were deter-
mined using the ΔΔCt-method. GAPDH mRNA levels
were used as the internal normalization control. The
primer sequences are listed in Additional file 1: Table S1
and described in the previous study [7, 8] and the designs
of the NSE, GFAP, and CNPase primers were made
following the directions of the ATRC Reagent Bank
(http://neurodiscovery.harvard.edu/atrc-reagent-bank).
Retrovirus and lentivirus production
Human full-length CHD7 cDNA (pF1KE9669 Flexi ORF
Clone, PROMEGA, www. promega.jp) was subcloned
into the pF5K CMV-neo Flexi vector vector (Promega),
and a pMX-Pax6 plasmid (mouse) was obtained from
Addgene (Cambridge, MA, www.addgene.org). Human
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PAX6 expression vector (pCS-PAX6, BC011953) was
purchased from Transomic (Huntsville, AL, www.tran-
somic.com). Recombinant lentiviruses were produced by
the shCHD7 lentivirus vector (EHS4430-98514866,
EHS4430-98714285, Open Biosystems. dharmacon.gelifes-
ciences. com) or control shRNA vector (RHS4346, Open
Biosystems). Retrovirus and lentivirus production including
shMIF were performed as described previously [7, 8].
Western blot analysis
Cell lysates were prepared using RIPA buffer (25 mM
Tris–HCl, 150 mM NaCl, 1% NP-40, 1% sodium deoxy-
cholate, and 0.1% SDS, pH 7.6) containing protease
inhibitors (Cocktail Tablet; Roche). Lysates were centri-
fuged at 14,000 × g for 15 min at 4 °C, and the protein
concentration of each sample was determined using a
Bio-Rad protein assay kit (Bio-Rad, Tokyo, Japan,
www.bio-rad.com) with bovine serum albumin as a
standard. Identical amounts of protein were electropho-
resed in 10% SDS-PAGE gels and transferred to a nitro-
cellulose membrane. Blots were blocked with Blocking
One™ (Nacalai Tesque, Kyoto, Japan, www.nacalai.co.jp)
at RT for 1 h, then incubated with primary antibodies
overnight at 4 °C as follows: CHD7 (1:100; BETHYL La-
boratories, Montgomery, TX,www.bethyl.com), p21(1:1000;
MBL, ruo.mbl.co.jp), p27 (1:1000; Cell signaling Tech-
nology), N-MYC (1:100; Abcam, www. Abcam.co.jp),
Lamin-B1(1:1000; Abcam), and actin (1:5000; Sigma,
www.sigmaaldrich.com). After three washes in TBST
(20 mM Tris–HCl, 150 mM NaCl, and 0.02% Tween-20,
pH 7.4), the blots were incubated with the appropriate
secondary antibodies conjugated with horseradish perox-
idase (1:4000, anti-rabbit and anti-mouse; GE Healthcare,
Tokyo, Japan, http://www.gelifesciences.co.jp) for 1 h at
room temperature. Signals were detected with ECL-Plus
Substrate (GE Healthcare) and exposed to Hyperfilm (GE
Healthcare).
Cell proliferation and apoptosis assay
Cell viability was assessed using Cell Titer-Glo Luminescent
Cell Viability Assay kits (Promega) and a luminometer
(EnVision™ multilabel reader, Perkin Elmer, Waltham,
MA, www.perkinelmer.com). Single cells dissociated
from neurospheres were seeded onto 96-well plates at a
density of 5x103 cells/well and activity was assayed on
the days described.
Immunocytochemistry and immunohistochemistry
Mice embryonic brains were removed and fixed in 4%
paraformaldehyde (PFA) in 0.1 M phosphate-buffered
saline (PBS), cryoprotected in 30% sucrose solution in
PBS, and embedded in O.C.T. compound (Sakura Finetek,
Tokyo, Japan, www.sakura-finetek.com). Adult mice were
killed by anesthetic overdose and perfused transcardially
with 4% PFA in PBS, pH 7.2. Brains were postfixed in the
perfusion solution overnight at 4 °C, then cryoprotected
for at least 24 h in 30% sucrose in PBS and embedded as
above. Brain blocks were sectioned in the appropriate
plane in 14 μm slices. After blocking with 10% goat normal
serum in 0.1 M PBS, brain slices were incubated in 5%
goat normal serum in 0.1 M PBS + 0.3% Triton X-100 with
the following primary antibodies: rabbit anti-CHD7 (1:100;
BETHYL laboratories), rabbit anti-Tbr2 (1:500; Abcam,
Cambridge, MA, www.abcam.com), pH3 (1:1000; Abcam),
Ki67 (1:1000; Abcam), anti-Nestin (1:100; Abcam), Pax6
(1:200; MBL), mouse anti-NeuN (1:100; Millipore). Appli-
cation of the primary antibodies was followed by incuba-
tion of the brain slices with secondary antibodies labeled
with Alexa Fluor 488, and 568 (1:400; Thermo Fisher
Scientific). For immunocytochemical studies, cells were
fixed with PBS containing 4% PFA for 20 min at room
temperature, and the cells were subjected to immuno-
fluorescence staining using the following primary anti-
bodies: rabbit anti-CHD7 (1:100; BETHYL laboratories),
mouse anti-β-tubulin type III (TuJ1) (1:1000; Sigma),
mouse anti-MAP2 (1:200; Sigma), mouse anti-NeuN
(1:100; Millipore), mouse anti-CNPase (1:250; Sigma),
mouse anti-GFAP (1:400; Sigma) and rabbit anti-GFAP
(1:400; Biomedical Technologies, Stoughton, MA, https://
www.alfa.com). After PBS washes, antibody binding was
visualized using either Alexa Fluor 488 or 568-conjugated
secondary antibodies (Thermo Fisher Scientific), and the
nuclei were stained with DAPI (4’,6-diamidino-2-phenylin-
dole, Thermo Fisher Scientific). In mouse NSPCs differen-
tiation assays, single dissociated cells of cultured
neurospheres were plated on poly-L-lysine coated glass
slips at a density of 2x105 cells/cm2 in NSP medium with-
out growth factors for 4 days, and then subjected to qPCR
analysis. In mouse NSPCs differentiation assays were per-
formed according to the previous study (7). In human
NSPCs differentiation assays were performed according to
the product protocol. In the immunocytochemical ana-
lyses, neurons and astrocytes were analyzed 2 weeks and
3 weeks, respectively, after differentiation, and at least 10
different viewing fields were counted using LMS700 con-
focal microscopy (Zeiss, Tokyo, Japan, www.zeiss.co.jp).
Statistical analysis
All values are expressed as mean ± S.D or S.E. Student’s
t tests were used to determine the statistical signifi-
cance of differences between groups (*P < 0.05, **P < 0.01).
Results
Chd7 is a downstream target of MIF in mouse NSPCs
We first performed qRT-PCR analysis to examine
whether Chd7 gene expression changes on MIF treat-
ment of NSPCs. MIF treatment increased the RNA level
of Chd7 in NSPCs (Fig. 1a). In contrast, cell treatment
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with ISO-1, a MIF antagonist, led to a decrease in Chd7
RNA levels in NSPCs (Fig. 1b). We have also observed
that the CHD7 protein changes correlate closely with
changes in its gene expression (data not shown). Together,
these results suggest that the Chd7 gene is a downstream
target of MIF signaling in NSPCs in vitro.
Chd7 is expressed in mouse embryonic brain NSPCs
Expression of the Chd7 protein in the mouse developmen-
tal brain at E14.5 was examined by immunofluorescence.
Chd7 was expressed in the ventricular zone of the cortex
and GE. The Chd7-positive cells also expressed nestin, a
known marker of NPSCs (Fig. 2a). This expression pattern
of Chd7 suggests that Chd7 is expressed in NSPCs in vivo.
Next, Chd7 protein expression was examined in cultured
NSPSs. Chd7 was expressed in neurospheres generated
from E14.5 GEs (Fig. 2b). In addition, Chd7 expression
was analyzed in the neural differentiated lineage in vitro,
indicating that many Chd7-positive cells were observed in
neurons, and some Chd7-positive cells were found in glial
lineage (glia and oligodendrocyte) cells (Fig. 2c–f,
Additional file 2: Figure S1C). However, western blot
analysis showed a significant reduction of Chd7 protein in
the differentiated cells compared to undifferentiated
NSPCs, suggesting a functional role of Chd7 in NSPCs
(Additional file 2: Figure S1D).
Chd7 supports cell survival and the self-renewal ability
of NSPCs
To identify the function of Chd7 in NSPCs, we first
examined changes in NSPC viability by lentivirus-
mediated silencing of Chd7. Chd7 gene silencing
decreased cell viability by half (0.51 ± 0.08 fold) 4 days
after infection (Fig. 3a). The same effect was con-
firmed by a different Chd7-targeting lentivirus vector
(Additional file 2: Figure S1). Moreover, we performed
the neurosphere-forming assay using a lentivirus
expressing Chd7-shRNA in NSPCs, Chd7 silencing by
lentivirus expression of shRNA-Chd7 in NSPCs attenuated
the formation of primary and secondary neurospheres by
0.50 ± 0.31 fold and 0.48 ± 0.24 fold, respectively
(Fig. 3b, c). Taken together, Chd7 may support NSPCs
cell survival and/or proliferation. Next, we tested
changes in the multi-lineage differentiation potential of
NSPCs upon Chd7 gene silencing. NSPCs infected with
lentivirus expression of shRNA-Chd7 were cultured for
5 days, and then replated and cultured for four additional
days in the absence of growth factors. Then, the gene
expression level of differentiation into each neuronal cell
type was assessed by qRT-PCR. In this assay, only the
neuron marker gene (NSE, neuron-specific enolase)
expression was reduced, although astrocytes (GFAP), and
oligodendrocytes (CNPase) marker genes expression were
not changed with a statistical value (Fig. 3d). The same
defect in neuronal differentiation by Chd7 gene silencing
was also observed on immunocytochemical analysis
(Additional file 3: Figure S2). Furthermore, we examined
whether Chd7 plays a role in cell proliferation in response
to MIF in NSPCs. While MIF treatment of control cells
resulted in an increase of cell viability 4 days after treat-
ment (1.31 ± 0.14 fold compared to control), this effect
was blunted by knockdown of Chd7 using lentivirus
expressing Chd7-shRNA, further supporting that Chd7 is
a downstream effector of MIF signaling in NSPCs
(Additional file 3: Figure S2).
Upstream and downstream signal of Chd7 in NSPCs
Chd7 was identified as a MIF downstream target in
NSPCs (Fig. 1). In addition, N-myc, Hes5, and Pax6 gene
























































Fig. 1 MIF regulates gene expression of Chd7 in mouse NSPCs. a, MIF treatment (400 ng/ml) for 24 h increases Chd7 gene expression. b MIF antagonist
(ISO-1) treatment (100 μM) for 24 h decreased Chd7 gene expression in NSPCs. Data are derived from three independent experiments. Error bars indicate
S.D. values; *P < 0.05, **P< 0.01 versus control; Student’s t-test
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with MIF (Fig. 4a–c). In human and murine, a Pax6
binding site locates in the upstream Chd7 promoter
region of transcription starting site (http://www.sabios-
ciences.com/chipqpcrsearch.php). Thus, we examined
whether Chd7 expression is regulated by Pax6 in NSPCs.
Retroviral over-expression of Pax6 increased Chd7 gene
expression (Fig. 4d) that resulted in an increased CHD7
protein expression (Fig. 4e), indicating Chd7 is a down-
stream target of MIF and Pax6 in NSPCs. Moreover,
Hes5 and N-myc gene expression were decreased by
Chd7 gene silencing using lentivirus expressing shChd7-
shRNA in NSPCs, suggesting a cascade of independent
events where MIF increases Pax6 expression which then
increases Chd7 expression, resulting in an increase in
N-myc and Hes5 gene expression (Fig. 4f, g).
Chd7 regulates population of IPCs in mouse
developmental neocortex
To analyze the role of Chd7 in the mouse developmental
brain, whirligig heterozygous Chd7 mutant mouse
(Chd7Whi/+) was analyzed at E14.5. Chd7Whi/+ carries
the heterozygous mutation c.2918 G > A, generating a
stop codon, having similar symptoms seen in CHARGE
syndrome patients. In addition, the Chd7Whi/Whi mouse
dies shortly at E10.5 [24], thus we analyzed the Chd7Whi/+
mouse at E14.5. In the neocortex, the number of cortical
IPCs (Tbr2+ cells) was decreased in the mutant mouse
compared to the wild type littermates (0.61 ± 0.08 fold
compared to control)(Fig. 5). In addition, the number of
Tbr2/Ki67 double-positive cells was also decreased in
the Chd7 mutant mouse compared to the wild type
βIII-tubulin Chd7 DAPI
GFAP Chd7 DAPI CNPase Chd7 DAPI
Chd7 Nestin DAPI Chd7 DAPI
MAP2 Chd7 DAPI NeuN Chd7 DAPI
GE
Fig. 2 Chd7 expression in NSPCs. a, Immunohistochemistry of Chd7-positive cells (red) were co-labeled with nestin (green) in E14.5 mouse brain.
b, Immunocytochemistry of neurospheres using Chd7 antibody. c–f, Chd7 expression in differentiated neural cells generated from embryonic day
14.5 brain GE-derived neurospheres 5 days after in vitro differentiation. Many Chd7-positive cells were observed in differentiated neurons identified by
βIII-tubulin (c), MAP2 and NeuN (d), although a small number of Chd7-positive cells was observed in differentiated glial cell types identified by
the following markers: GFAP (e), and CNPase (f). Scale bar; 200 μm (a), 100 μm (b), 50 μm (c, d, e), 20 μm (Enlarged image a, d)
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littermates (0.31 ± 0.01 fold compared to control), indi-
cating a decrease of neuronal progenitors (Fig. 5). In
addition, the number of Pax6/pH3-double positive cells
(pH3, a marker for M-phase cells, [25]) was also
smaller in the apical ventricular zone of E14.5.
Chd7Whi/+ mouse compared to wild-type littermates
(0.69 ± 0.17 fold compared to control), suggesting a reduc-
tion in some population of NSPCs caused by the decrease
of CHD7 protein (Additional file 4: Figure S3A). In
addition, a mature neural cell population (NeuN-posi-
tive cells) was also decreased in the Chd7Whi/+ mouse cor-
tical plate compared to wild-type littermates (0.74 ± 0.08
fold compared to control), indicating a decrease in NSPCs
and IPCs in the Chd7Whi/+ mouse (Additional file 4:
Figure S3B).
Chd7 supports cell survival and/or proliferation of human
ES-NSPCs
We also tested whether CHD7 can support the cell pro-
liferation and or survival in human ES-NSPCs as seen
in mouse NSPCs. We used human ES-NSPCs, which
were cultured as attachment cells. The differentiation
potential of the human ES-NSPCs into neuron and glia
was confirmed and cell viability of human ES-NSCs
was also increased by recombinant human MIF treat-
ment (data not shown). Transient CHD7 gene over-
expression in human ES-NSPCs increased in the cell
proliferation (1.49 ± 0.04 fold compared to control)
(Fig. 6a); in contrast, human ES-NSPCs infected with
lentivirus expression of shRNA-CHD7 decreased cell
proliferation (0.31 ± 0.01 fold compared to control)
(Fig. 6b), which is consistent with our experimental re-
sults in mouse. Moreover, lentiviral MIF gene silencing
decreased CHD7 gene expression in human ES-NSPCs
similar to mouse NSPCs (Fig. 6c). Furthermore, as seen
in mouse NSPCs, transient over-expression of human
PAX6 up-regulated the CHD7 gene expression in human
ES-NSPCs (Fig. 6d). In human ES-NSC, gene silencing of
CHD7 also downregulated N-MYC and HES5 gene ex-
pression as seen in mouse NSPCs (Fig. 6e, f ). Similar to
the case in the mouse system, MIF silencing in human
ES-NSPCs downregulated the gene expression of PAX6,
N-MYC, and HES5 (Additional file 5: Figure S4). In
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1
Fig. 3 Chd7 regulates mouse NSPCs proliferation and self-renewal in vitro. a, Chd7 targeting using lentiviral shRNA significantly reduced NSPC
growth compared to control shRNA, as assessed using a Cell Titer-Glo Assay Kit 4 days after infection. b, In the primary neurosphere formation
assay, single dissociated cells of neurospheres generated from E14.5 brain were plated onto a 96-well plate and infected with lentiviruses encoding
control shRNA or Chd7 shRNA. The cells were cultured in the presence of both EGF and FGF2 c, In the secondary neurosphere assay, neurospheres in-
fected with a lentivirus encoding control shRNA or Chd7 shRNA were cultured in the presence of both EGF and FGF2 for 5 days. Then neurospheres
were dissociated into single cells and seeded onto a 96-well plate at a cell density of 20 cells/μl in the presence of EGF and FGF2. d,
Neurospheres infected with lentivirus expressing either control or Chd7 targeting shRNA were cultured in the presence of both EGF and
FGF2 for 5 days and then dissociated and cultured onto the poly-D-lysine coated glass slip for 4DIV in the absence of growth factors.
The gene expression of neural marker (NSE), an astrocyte marker (GFAP), or an oligodendrocyte marker (CNPase) was quantified by qRT-PCR. For the
graphs, the data were compiled from three independent experiments. Error bars indicate S.E. values; **P < 0.01 versus control; Student’s t-test
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CHD7 gene silencing was confirmed by immunocyto-
chemical analysis, and the number of differentiated neu-
rons was decreased in human ES-NSPCs (0.52 ± 0.13 fold
compared to control) as seen in mouse NSPCs (Additional
file 6: Figure S5).
CHD7 supports cell survival and proliferation of GICs
GICs are known to maintain glioma, and the identifica-
tion of key molecule(s) in the regulation of GICs may
contribute to the development of novel glioma treatment
strategies [9]. To test the function of CHD7 in human
glioma, we firstly examined the CHD7 gene expression
in normal astrocytes, NSPCs (human fetal brain derived),
glioma cells (U87MG, U251), and GICs. Intriguingly,
CHD7 was highly expressed in GICs (Fig. 7a). In silico
analysis shows that CHD7 and CHD9 are well expressed in
brain tumor, and CHD7 is expressed highly in Glioblastoma
multiforme (GBM) compared to normal brain (Additional
file 7: Figure S6). We examined the effect of CHD7
gene silencing in GICs, and found that lentiviral CHD7
gene silencing decreased the cell proliferation (0.56 ± 0.07
fold compared to control) (Fig. 7b). In addition, CHD7
gene silencing in GICs upregulated cell cycle arrest genes
(p21 and p27) (Fig. 7c, d) and downregulated N-MYC,
whose gene amplification was reported in GBM [26]
(Fig. 7e).
Discussion
In the present study, we identified Chd7, which is






pMX   pMX-Pax6
1.00       1.80
shCtrl     shChd7 shCtrl     shChd7
Fig. 4 Analysis of MIF-Chd7 signaling cascade in mouse NSPCs. a–c, MIF increases the expression of Pax6 (a), Hes5 (b) and N-myc (c) in NSPCs 24 h
after MIF treatment. Each mRNA expression level was normalized against GAPDH mRNA levels, then expressed relative to the normalized value
of controls. d, e, Retroviral Pax6 overexpression in NSPCs led to an increase in Chd7 gene (d) and protein (e) 5 days after infection. f, g, Lentiviral CHD7-shRNA
expression decreased the gene expression of Hes5 (f) and N-myc (g) in NSPCs 5 days after infection. For the graphs, the data were compiled
from three independent experiments. Error bars indicate S.D. values; **P < 0.01 versus control; Student’s t-test
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factor for NSPCs. Moreover, we showed that CHD7 gene
expression is regulated by MIF in mouse NSPCs and
human ES-NSPCs. In addition, we also showed that
CHD7 supports the cell proliferation of GICs.
Some CHD family members have been reported to
play a role in the neural development in mouse brain.
Chd4 was required for Ezh2 mediated inhibition of
gliogenesis in mouse embryonic brain [27]. In addition,
Chd2 was required for embryonic neurogenesis regulating
REST and also expressed in cultured neurospheres in
mouse [28]. Depletion of Chd5 led to an inhibition of
neurogenesis accompanied with the accumulation of
undifferentiated cells in the mouse embryonic brain [29].
In adult mouse SVZ and hippocampus, the expression of
Chd7 in actively dividing NSPCs was reported, and Chd7
contributed to the neurogenesis accompanied with the
activation of Sox4 and Sox11 [16]. In the study, a slight
increase in the number of Tbr2 cells in the SGZ of Chd7
mutant mouse (Nestin-CreER2:Chd7fl/fl) was reported
[16]; however, the decrease of the Tbr2/KI67 double posi-
tive cells was observed in Chd7 mutant (Whi) mouse
embryonic brain accompanied with the decreased neuro-
genesis observed in the present study. In addition, other
groups also studied the Nestin-CreER2:Chd7fl/fl mice and
reported a decrease in number of KI67-positive cells in
SVZ of embryonic brain [30]. Furthermore, another group
showed that Chd7 maintained NSPCs quiescence status in
mouse hippocampus using a different mouse model
system (GLAST-CreER2:Chd7fl/fl) [17], showing Hes5 gene
regulation by Chd7. We note that different phenotypes
may occur depending on the mutant mouse type. How-
ever, in both of the different mouse models used here,
Chd7 knockout led to a decrease of neurogenesis in the
adult brain based on the NSPCs regulation, which is
consistent with embryonic brain. In human CHARGE
syndrome, the many different types of CHD7 mutations
have been reported, and CHD7 protein expression in the
lateral ventricle and hippocampus in human adult brain
has been observed (http://www.proteinatlas.org). Thus,
the analysis of the effects of CHD7 mutations in human
brain on psychiatric disorders regulated by NSPCs may be
important in the future.
We reported the TP53 regulation by MIF in a tran-
scription independent manner in human glioma cells
[9]. Intriguingly, MIF was expressed in nucleus and cyto-
plasmic fractions and antagonized TP53 intracellularly
in the system studied. In addition, CHD7 could repress
TP53 gene expression by the direct-bonding on the
TP53 promoter, and the CHD7-TP53 signaling axis was
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Fig. 5 Decrease of Tbr2-positive cells in Chd7 mutant mouse in the developing cerebral cortex. a, The expression of Tbr2-positive IPCs cells (red)
were co-labeled with Ki67 antibody (green) in Chd7 mutant (whi/+) and wild-type (WT) in E14.5 mouse embryonic brain. The nuclei were stained
using DAPI (blue). b, The number of Tbr2/Ki67 and Tbr2-positive cells were decreased in Chd7 mutant (whi, n = 5) compared to wild-type (n = 6).
Error bars indicate S.D. values; **P < 0.01 versus control; Student’s t-test. Scale bar; 20 μm
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fibroblasts from patients with CHARGE syndrome [31].
We examined the gene expression of TP53 in CHD7
gene silenced human ES-NSPCs and GICs; however, the
TP53 gene was not upregulated in these systems (data
not shown). In CHD5 study, CHD5 showed the dual
roles of gene activation and repression in neurogenesis
[29], showing the possibility CHD7 may have these dual
roles depending on the context. A more precise analysis
of TP53 regulation related to cell proliferation and
apoptosis by CHD7 regulated by MIF in mouse and human
NSPCs, GICs in both a transcription-dependent and -inde-
pendent fashion may be of interest for future study.
In the present study, we observed the reduction of
neurogenesis by Chd7 gene silencing in mouse NSPCs
in vitro and the reduction of IPCs and Pax6/pH3 cells in
Chd7 mutant embryonic brain in vivo. Using in vitro
murine NSPC culture, we have shown that Chd7 regu-
lates the gene expression of N-myc. N-myc conditional
deletion reduced the IPC population in mouse develop-
mental brain [32]. Thus, IPCs may be subject to regula-
tion by the Chd7-N-myc axis in the embryonic mouse
cortex. However, it has been reported that Chd7 coop-
erates with Sox10 to regulate the initiation of myelination
and remyelination (genesis of differentiated OLs from
OPCs, oligodendrocyte precursor cells) in vivo [18],
suggesting possible diverse roles for Chd7 that vary in a
manner dependent on spatial and developmental context.
Indeed, Chd7 cooperates with PBAF in controlling the for-
mation of neural crest cells based on the binding to the
target gene’s enhancer region [13]. In addition, many
binding partner proteins of CHD7 have been reported
[20]. As a component of multimolecular complexes
involving various binding partners, CHD7 may thus
contribute to the determination of some cell lineages.
High expression of Chd7 in neurons differentiated from
mouse NSPCs compared to glial lineages cells was
observed in vitro. Further study focused on epigenetic
regulation on Chd7 may be also important to the
understanding of this phenomenon. Moreover, we
showed the CHD7 expression level in GICs compared
to cultured primary astrocyte cells and neural stem/
progenitor cells from human fetal brain in Fig. 7a, because
astrocytes [33] and neural stem/progenitor cells [34, 35]
may be the major cell origins of glioblastomas. Interest-
ingly, mouse cortical neuron also generate glioma [36].
Thus, neural progenitor cells may be also cellular
source for GICs. Comparing CHD7 expression level








































































































































Fig. 6 CHD7 signaling cascade in human ES-NSPCs. a, b, Over-expression of CHD7 increases cell proliferation in human ES-NSPCs 5 days after
transfection (a). In contrast, CHD7 targeting using lentiviral shRNA significantly reduced human ES-NSPCs growth compared to control shRNA, as
assessed using a Cell Titer-Glo Assay Kit 3 days after infection (b). c, Lentiviral MIF-shRNA expression led to a decrease of CHD7 gene expression
2 days after infection. d, PAX6 over-expression in human ES-NSPC led to an increase of CHD7 gene expression 2 days after transfection. e, f, Lentiviral
CHD7-shRNA expression decreased the gene expression of N-MYC (e) and HES5 (f) in human ES-NSPC 2 days after infection. Data are representative
of three independent experiments. Error bars indicate S.D. values; **P < 0.01 versus control; Student’s t-test
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neural progenitor cells accompanied would be interesting
for future study.
It is known that some CHD dysfunction occurs in can-
cer [37]. In silico analysis in the present showed the
higher expression of CHD7 and CHD9 in brain tumor
(Additional file 7: Figure S6). In addition, in TCGA data-
base analysis, the overall survival of high-CHD7 expres-
sion patients tended to be shorter compared to that of
low-CHD7 expression patients in GBM (data not
shown), suggesting that CHD7 may support the prolifera-
tion of glioma cells and GICs. In contrast, CHD5 has been
reported as a tumor suppressor gene in some tumors,
such as in lung cancer [38]. In addition, intriguingly, low-
expression of CHD7 was correlated to the survival of
gemcitabine treated pancreatic ductal adenocarcinoma
patients [39], suggesting the potential of CHD7 as a
tumor suppresser gene like CHD5 in some tumors.
Thus, functional analysis and identification of target
genes and upstream regulators of CHD7 in CHD7-high
expression tumors including liver and colorectal cancer
may be of interest in this context.
We have reported the roles of MIF, which supports
the cell proliferation and/or survival in mouse NSPCs
and GICs. In mouse NSPCs, MIF regulates many signaling
molecules, including Erk, Stat3, AMPK, and Sox6 [7, 8].
In the developmental mouse brain, the expression pattern
of Sox6 and Chd7 differ, although both genes are regu-
lated by MIF in NSPCs in vitro. However, SOX6 gene
transcript was downregulated by CHD7 gene silencing in
human ES-NSPCs in vitro (data not shown). Thus, we are
currently analyzing the detailed signaling mechanism
regulated by MIF in NSPCs and GICs including the
regulation of both miR and lncRNA in addition to


































































































































Fig. 7 Functional analysis of CHD7 in glioma tumor initiating cells. a, Relative gene expression level of CHD7 was evaluated in GICs, NSPCs and glioma
cell compared to astrocytes by qRT-PCR. b, CHD7 supports cell proliferation and/or survival in GICs (GICs-1). Lentiviral CHD7-shRNA expression
significantly reduced cell proliferation and/or survival in GICs 5 days after infection. c–e, Gene expression of cell cycle arrest genes (c, p21; D, p27) was
up-regulated and N-MYC was down-regulated (e) by lentiviral CHD7-shRNA gene silencing in GICs 5 days after infection. Error bars indicate S.D. values;
*P < 0.05, **P < 0.01 versus control (n = 3); Student’s t-test. The protein level of p21 (c), p27 (d), and N-MYC (e) was quantified using Image J software,
and relative protein levels (normalized by β-actin) are shown above the panel
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MIF-CHD7 pathway in NSPCs may help to clarify MIF
function in these cells, and contribute to the development
of new applications for MIF biology in regenerative medi-
cine and induced pluripotent stem cells (iPSCs).
In this study, we focused on CHD7 function in NSPCs
derived from mouse embryonic brains, human ES-NSPCs,
and GICs in vitro, showing the MIF function as a cell pro-
liferation factor. Importantly, CHD7 is regulated by MIF
in mouse NSPCs and human ES-NSPCs. Investigations of
CHD7 function in gliogenesis at different developmental
stages and in other neural diseases, such as stroke and
spinal cord injury, that are associated with regenerative
neurogenesis remain for future study. It will also be useful
to conduct analyses of the regulation of CHD7 binding to
the histone (H3H4me1) and itsenhancer(s) in NSPCs.
Finally, functional analyses of CHD7 especially in human
gliomas and GICs, may help pave the way for evaluating
CHD7 as a therapeutic target.
Additional files
Additional file 1: Table S1. Primer sequence. (DOCX 14 kb)
Additional file 2: Figure S1. Chd7 gene knockdown decreases NSPCs
proliferation. A, Chd7 targeting using lentiviral shRNA significantly
reduced mouse NSPC growth compared to control shRNA, as assessed
using a Cell Titer-Glo Assay Kit 4 days after infection. B, The gene expression
level of Chd7 was quantified by qRT-PCR in NSPCs 4 days after infection.
Error bars indicate S.D. values; *P < 0.05, **P < 0.01 versus control; Student’s
t-test from three independent experiments. C, We counted the number of
Chd7-positive cells in each of the differentiated neural cells derived from
embryonic day 14.5 brain GE-NSPCs after 5 days of differentiation without
growth factors. Error bars indicate S.D. values and value shows the average
of three independent experiments. D, Chd7 protein expression was reduced
in the differentiated neuronal cells in the absence of growth factors derived
from embryonic day 14.5 brain GE-NSPCs 2 days after differentiation. The
level of Chd7 was quantified using Image J software (NIH, Bethesda, MD)
and relative Chd7 protein levels (normalized by β-actin) are shown below
the panel. (PPT 278 kb)
Additional file 3: Figure S2. MIF regulated Chd7 can support cell survival
and/or proliferative ability in NSPCs. A, Changes in cell proliferation with or
without MIF treatment (400 ng/ml) in mouse NSPCs were observed using a
CellTiter Glo Luminescent Cell kit. The increase in cell viability by MIF
treatment was inhibited by lentiviral Chd7 gene knockdown 4 days
after infection (n = 3). Error bars indicate S.D. values; *P < 0.05, **P < 0.01
versus control; Student’s t-test from three independent experiments. B.
Neurospheres infected with lentivirus expressing either control or Chd7-
targeting shRNA were cultured in the presence of both EGF and FGF2 for
5 days, and then dissociated and cultured onto the poly-D-lysine coated
glass slip for 5DIV in the absence of growth factors. The expression of neural
marker (βIII-tubulin), an astrocyte marker (GFAP), or an oligodendrocyte
marker (CNPase) was evaluated by immunocytochemistry. Error bars
indicate S.D. values and data was derived at least three independent
experiments. (PPT 224 kb)
Additional file 4: Figure S3. Analysis of mitotic cells in the apical
ventricular zone and matured neural cells in the cortical plate in Chd7
mutant mouse. A, Cells immunopositive for phosphorylated histone
H3 staining (pH3, green signal) indicate cells in mitosis. The number
of pH3/Pax6 (red)-double positive cells in Chd7 mutant mouse (Chd7Whi/+,
n = 8) was counted compared to the wild-type littermates (n = 6) at
embryonic day 14.5 brain. B, Cells that are immunopositive for NeuN
in the cortical plate (CP) were counted at embryonic day 14.5 brain
(wild-type littermates, n = 4; Chd7Whi/+, n = 4). Error bars indicate S.D.
values; *P < 0.05 versus control; Student’s t-test. Scale bar; 20 μm.(A),
50 μm (B). (PPT 1259 kb)
Additional file 5: Figure S4. Identification of MIF regulated genes in
human ES-NSPCs. A-D, Change of targets and MIF gene expression level
by lentiviral MIF gene knockdown were quantified in human ES- NSPCs
2 days after infection. Error bars indicate S.D. values; *P< 0.05, **P< 0.01 versus
control; Student’s t-test from three independent experiments. (PPT 198 kb)
Additional file 6: Figure S5. Differentiation potential of human ES- NSPCs
derived fromCHD7 knockdown. A, Human ES-NSPCs were infected with
lentivirus expressing either CHD7 shRNA or control shRNA for 2 days and
then differentiated in each differentiation medium for 2 weeks (neuron) or
3 weeks (astrocytes). Representative images of differentiated cells, which
were fixed and subjected to immunocytochemical analyses labeled with a
neuronal marker (βIII-tubulin) or astrocyte marker (GFAP), were shown. Scale
bar: 20 μm. B, βIII-tubulin 1and GFAP positive number in DAPI-positive cells
was counted, and the data were expresses as percentages. (PPT 1018 kb)
Additional file 7: Figure S6. In silico analysis of CHD family expression
in GBM. A, Relative CHD family mRNA expression data in different human
cancers were obtained from the public version of the Oncomine
(www.oncomine.org). B, CHD7 gene expression of brain tumors compared
to normal brain was analyzed in silico using the REMBRANDT data base
(http://rembrandt.nci.nih.gov). (PPT 332 kb)
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